S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Laser breakthrough could send stock soaring 2,467% (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Having Trouble in Your Trading? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Laser breakthrough could send stock soaring 2,467% (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Having Trouble in Your Trading? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Laser breakthrough could send stock soaring 2,467% (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Having Trouble in Your Trading? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Laser breakthrough could send stock soaring 2,467% (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Having Trouble in Your Trading? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:SNTI

Senti Biosciences (SNTI) Stock Forecast, Price & News

$0.88
-0.07 (-7.34%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.86
$0.95
50-Day Range
$0.88
$1.26
52-Week Range
$0.86
$9.96
Volume
68,436 shs
Average Volume
99,844 shs
Market Capitalization
$39.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Senti Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
409.1% Upside
$4.50 Price Target
Short Interest
Bearish
2.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.54) to ($0.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

729th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

116th out of 167 stocks


SNTI stock logo

About Senti Biosciences (NASDAQ:SNTI) Stock

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer cells, while sparing healthy cells in the body. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SNTI Stock News Headlines

Senti Biosciences (SNTI) & Its Rivals Financial Review
Instantly Find Hidden Trade Opportunities
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Instantly Find Hidden Trade Opportunities
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Senti Biosciences (NASDAQ:SNTI) PT Lowered to $2.00
Expert Ratings for Senti Biosciences
See More Headlines
Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SNTI Company Calendar

Last Earnings
3/22/2023
Today
5/31/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNTI
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+409.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-58,210,000.00
Net Margins
-1,457.24%
Pretax Margin
-1,457.24%

Debt

Sales & Book Value

Annual Sales
$4.29 million
Book Value
$2.54 per share

Miscellaneous

Free Float
N/A
Market Cap
$39.04 million
Optionable
Not Optionable
Beta
2.48

Key Executives

  • Dr. Timothy K. Lu M.D. (Age 41)
    Ph.D., Co-founder, CEO, Pres & Director
    Comp: $694.21k
  • Dr. Philip Lee Ph.D. (Age 40)
    Co-Founder & CTO
    Comp: $571.6k
  • Ms. Susan D. Berland (Age 67)
    Sr. Financial Exec. & Independent Director
    Comp: $27.84k
  • Dr. James J. Collins Ph.D. (Age 56)
    Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
  • Dr. Wilson Wong Ph.D.
    Scientific Co-Founder & Member of Scientific Advisory Board
  • Dr. Deborah A. Knobelman Ph.D. (Age 48)
    CFO & Treasurer
  • Dr. Kanya Rajangam M.D. (Age 49)
    Ph.D., Chief Medical & Devel. Officer
  • Susan Kahlert
    Controller













SNTI Stock - Frequently Asked Questions

Should I buy or sell Senti Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNTI shares.
View SNTI analyst ratings
or view top-rated stocks.

What is Senti Biosciences' stock price forecast for 2023?

4 analysts have issued 1 year price targets for Senti Biosciences' shares. Their SNTI share price forecasts range from $2.00 to $7.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 409.1% from the stock's current price.
View analysts price targets for SNTI
or view top-rated stocks among Wall Street analysts.

How have SNTI shares performed in 2023?

Senti Biosciences' stock was trading at $1.41 on January 1st, 2023. Since then, SNTI shares have decreased by 37.3% and is now trading at $0.8839.
View the best growth stocks for 2023 here
.

When is Senti Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our SNTI earnings forecast
.

How were Senti Biosciences' earnings last quarter?

Senti Biosciences, Inc. (NASDAQ:SNTI) announced its earnings results on Wednesday, March, 22nd. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.05. The firm earned $0.06 million during the quarter, compared to analyst estimates of $1.92 million. Senti Biosciences had a negative trailing twelve-month return on equity of 48.76% and a negative net margin of 1,457.24%.

What ETFs hold Senti Biosciences' stock?

ETFs with the largest weight of Senti Biosciences (NASDAQ:SNTI) stock in their portfolio include ARK Genomic Revolution ETF (ARKG),

What is Senti Biosciences' stock symbol?

Senti Biosciences trades on the NASDAQ under the ticker symbol "SNTI."

Who are Senti Biosciences' major shareholders?

Senti Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (7.85%), ARK Investment Management LLC (4.31%) and Triatomic Management LP (0.48%).
View institutional ownership trends
.

How do I buy shares of Senti Biosciences?

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Senti Biosciences' stock price today?

One share of SNTI stock can currently be purchased for approximately $0.88.

How much money does Senti Biosciences make?

Senti Biosciences (NASDAQ:SNTI) has a market capitalization of $39.04 million and generates $4.29 million in revenue each year. The company earns $-58,210,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

How can I contact Senti Biosciences?

Senti Biosciences' mailing address is 2875 EL CAMINO REAL, REDWOOD CITY CA, 94061. The official website for the company is www.sentibio.com. The company can be reached via phone at 650-239-2030 or via email at irbd@dspc.bio.

This page (NASDAQ:SNTI) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -